Malli Chaithra, Pandit Lekha, D'Çunha Mary A, Sudhir Akshatha
Center for Advanced Neurological Research, KS Hegde Medical Academy, Nitte (Deemed to be University), Mangalore, Karnataka, India.
Ann Indian Acad Neurol. 2021 Sep-Oct;24(5):740-744. doi: 10.4103/aian.AIAN_170_21. Epub 2021 Jun 22.
Co-occurrence of other autoimmune disorders (AID) and autoantibodies in patients with autoimmune demyelinating CNS disorders have not been studied previously in patients of Indian origin.
To determine the frequency of concomitant autoimmune disorders, anti-nuclear antibody (ANA) and antithyroid antibody (ATAb) and to evaluate the impact on clinical course of disease.
A total of 111 patients with MS and 152 patients with non-MS demyelinating disorders were included. Demographics, clinical course and disability were recorded. History of other autoimmune disorders (AIDs) in patients and first degree relatives was noted. Serum ANA and ATAb were tested.
Concomitant AIDs were seen in 21% of MS and 19% of non-MS patients. Autoimmune thyroid disease was most frequent and seen in 10.8% of MS and 6.6% of non-MS disorders. Frequency of ATAb was significantly higher among MS group (MS 25.5% vs non-MS 13.2% = 0.04) but that of ANA was similar between the 2 groups (MS 19.8% vs non-MS 26.9% = 0.17). A positive family history of autoimmune disorders was noted in 20% of MS and 15.1% of non-MS disorders. Clinical course was unaffected by presence of concomitant AID and autoantibodies.
Cooccurrence of autoantibodies and AID are seen in a significant number of patients with MS and non-MS disorders and influences clinical management.
此前尚未对印度裔自身免疫性中枢神经系统脱髓鞘疾病患者中其他自身免疫性疾病（AID）和自身抗体的共现情况进行研究。
确定合并自身免疫性疾病、抗核抗体（ANA）和抗甲状腺抗体（ATAb）的频率，并评估其对疾病临床进程的影响。
共纳入111例多发性硬化症（MS）患者和152例非MS脱髓鞘疾病患者。记录人口统计学信息、临床病程和残疾情况。记录患者及其一级亲属中其他自身免疫性疾病（AIDs）的病史。检测血清ANA和ATAb。
21%的MS患者和19%的非MS患者存在合并AIDs。自身免疫性甲状腺疾病最为常见，在10.8%的MS患者和6.6%的非MS疾病患者中出现。MS组中ATAb的频率显著更高（MS为25.5%，非MS为13.2%，P = 0.04），但两组间ANA的频率相似（MS为19.8%，非MS为26.9%，P = 0.17）。20%的MS患者和15.1%的非MS疾病患者有自身免疫性疾病的阳性家族史。合并AID和自身抗体的存在对临床病程无影响。
在大量MS和非MS疾病患者中可见自身抗体和AID的共现，且会影响临床管理。
